Applied Therapeutics Inc (NASDAQ: APLT) on Friday, plunged -1.57% from the previous trading day, before settling in for the closing price of $0.1. Within the past 52 weeks, APLT’s price has moved between $0.09 and $1.50.
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 26.57%. The company achieved an average annual earnings per share of 29.93%. With a float of $133.43 million, this company’s outstanding shares have now reached $144.30 million.
Applied Therapeutics Inc (APLT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Applied Therapeutics Inc is 7.54%, while institutional ownership is 62.10%. The most recent insider transaction that took place on Dec 16 ’25, was worth 4,816. In this transaction Director of this company sold 43,000 shares at a rate of $0.11, taking the stock ownership to the 65,000 shares. Before that another transaction happened on Dec 16 ’25, when Company’s Director proposed sale 43,000 for $0.22, making the entire transaction worth $9,331.
Applied Therapeutics Inc (APLT) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.33 earnings per share (EPS) for the period topping the consensus outlook (set at -0.17) by 0.5. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.93% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.95% during the next five years compared to 26.57% growth over the previous five years of trading.
Applied Therapeutics Inc (NASDAQ: APLT) Trading Performance Indicators
Applied Therapeutics Inc (APLT) is currently performing well based on its current performance indicators. A quick ratio of 0.96 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.10, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.43 in one year’s time.
